Positive News SentimentPositive NewsNASDAQ:OPRX OptimizeRx (OPRX) Stock Forecast, Price & News $7.15 -0.38 (-5.05%) (As of 12:33 PM ET) Add Compare Share Share Today's Range$7.14▼$7.6450-Day Range$7.43▼$14.1252-Week Range$7.14▼$22.77Volume29,553 shsAverage Volume177,867 shsMarket Capitalization$118.98 millionP/E RatioN/ADividend YieldN/APrice Target$15.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OptimizeRx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside113.4% Upside$15.60 Price TargetShort InterestBearish4.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.90Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsComputer And Technology Sector218th out of 603 stocksBusiness Services, Not Elsewhere Classified Industry38th out of 92 stocks 4.5 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.60, OptimizeRx has a forecasted upside of 113.4% from its current price of $7.31.Amount of Analyst CoverageOptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.24% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in OptimizeRx has recently increased by 8.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.3 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions77.82% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.83) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OptimizeRx (NASDAQ:OPRX) StockOptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.Read More OPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comOptimizeRx Unveils a Significant Enhancement to its Omni-channel Healthcare Engagement PlatformSeptember 21, 2023 | finance.yahoo.comAre OptimizeRx Corporation (NASDAQ:OPRX) Investors Paying Above The Intrinsic Value?October 3, 2023 | Oxford Club (Ad)The Ultimate Passive Income PlayThe #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.August 24, 2023 | finance.yahoo.comOptimizeRx Expands AI Powered Omnichannel PlatformAugust 20, 2023 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Trimmed Their Revenue Forecasts By 13%August 16, 2023 | marketwatch.comOptimizeRx Shares Drop 22% As Non-Core Business Drags on ResultsAugust 16, 2023 | msn.comStifel Maintains OptimizeRx (OPRX) Buy RecommendationAugust 16, 2023 | msn.comRoth MKM Maintains OptimizeRx (OPRX) Buy RecommendationOctober 3, 2023 | Oxford Club (Ad)The Ultimate Passive Income PlayThe #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.August 15, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.comOptimizeRx Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy OptimizeRx StockJuly 31, 2023 | finance.yahoo.comOptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ETJuly 14, 2023 | fool.comOptimizeRx (NASDAQ: OPRX)June 30, 2023 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst institutional investors who own 85%June 20, 2023 | finance.yahoo.comLifeMD Appoints William J. Febbo to its Board of DirectorsMay 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: OptimizeRx (OPRX) and UiPath (PATH)May 25, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on OptimizeRx (OPRX)May 24, 2023 | finance.yahoo.comOptimizeRx’s CEO Provides 2023 Midyear Strategic UpdateMay 24, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx's CEO Provides 2023 Midyear Strategic UpdateMay 24, 2023 | benzinga.comOptimizeRx's CEO Provides 2023 Midyear Strategic UpdateMay 18, 2023 | finance.yahoo.comOptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100May 18, 2023 | finance.yahoo.comRevenues Tell The Story For OptimizeRx Corporation (NASDAQ:OPRX)May 12, 2023 | msn.comRecap: OptimizeRx Q1 EarningsMay 11, 2023 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from RBC CapitalMay 11, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue EstimatesSee More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Company Calendar Last Earnings8/14/2023Today10/03/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees109Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.60 High Stock Price Forecast$20.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+107.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,440,000.00 Net Margins-23.30% Pretax Margin-23.29% Return on Equity-10.05% Return on Assets-9.51% Debt Debt-to-Equity RatioN/A Current Ratio15.44 Quick Ratio15.44 Sales & Book Value Annual Sales$62.45 million Price / Sales2.01 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book1.02Miscellaneous Outstanding Shares16,640,000Free Float15,906,000Market Cap$125.30 million OptionableNot Optionable Beta1.02 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. William J. Febbo (Age 54)CEO & Director Comp: $694.4kMr. Edward Stelmakh C.M.A. (Age 57)M.B.A., MBA, CFO & COO Comp: $547.05kMr. Stephen L. Silvestro (Age 45)Chief Commercial Officer Comp: $458.6kMr. Andrew Jacob D'SilvaSr. VP of Corp. Fin.Mr. Todd Inman (Age 67)Chief Technology Officer Ms. Marion K Odence-Ford (Age 58)Gen. Counsel & Chief Compliance Officer Maira AlejandraMedia Relations Mang.Ms. Sheryl KearneyHR Mang.Mr. Terence J. Hamilton (Age 58)Sr. VP of Pharma Ms. Rebecca WhitneySr. VP of Commercial OperationsMore ExecutivesKey CompetitorsZeroFoxNASDAQ:ZFOXDHI GroupNYSE:DHXUxinNASDAQ:UXINSteel ConnectNASDAQ:STCNEdgioNASDAQ:EGIOView All CompetitorsInstitutional OwnershipBarclays PLCSold 5,137 shares on 9/21/2023Ownership: 0.020%Portside Wealth Group LLCBought 115,605 shares on 9/1/2023Ownership: 0.695%Osaic Holdings Inc.Sold 3,520 shares on 8/21/2023Ownership: 0.025%Alliancebernstein L.P.Bought 2,459 shares on 8/15/2023Ownership: 0.150%Connors Investor Services Inc.Bought 3,000 shares on 8/15/2023Ownership: 0.108%View All Institutional Transactions OPRX Stock - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price forecast for 2023? 8 brokers have issued 1 year price targets for OptimizeRx's shares. Their OPRX share price forecasts range from $13.00 to $20.00. On average, they expect the company's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2023? OptimizeRx's stock was trading at $16.80 on January 1st, 2023. Since then, OPRX stock has decreased by 55.2% and is now trading at $7.53. View the best growth stocks for 2023 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $14.97 million. OptimizeRx had a negative net margin of 23.30% and a negative trailing twelve-month return on equity of 10.05%. What ETFs hold OptimizeRx's stock? ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC). What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). What is OptimizeRx's stock symbol? OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX." How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OptimizeRx's stock price today? One share of OPRX stock can currently be purchased for approximately $7.53. How much money does OptimizeRx make? OptimizeRx (NASDAQ:OPRX) has a market capitalization of $125.30 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How many employees does OptimizeRx have? The company employs 109 workers across the globe. How can I contact OptimizeRx? OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529. This page (NASDAQ:OPRX) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.